Clinical Trial Update: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and feasibility of combining ibrutinib with immunochemotherapy (temozolomide, etoposide, doxorubicin liposomal, dexamethason…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Doxil (liposomal doxorubicin)
• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)
• Temodar (Temozolomide)
• Toposar (Etoposide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Central Nervous System Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING